Bile duct cancer market

Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3) and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Nov 2021
CMI4790
184 Pages
Excel & Pdf
Pharmaceutical

Summary

Bile duct cancer is a form of cancer in which epithelial cells are mutated which shows epithelial differentiation in the bile duct. It is type of rare disease.

Furthermore, major key players are focusing on adoption of inorganic strategies such as collaborations, in order to strengthen their product offerings and presence in the global bile duct cancer market

In Mach 2021, QED Therapeutics a biotechnology company, announced that it collaborated with Helsinn Group, a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care, rare disease products, and a broad development pipeline. The collaboration is to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer).

The global bile duct cancer market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period (2021-2028).

Figure 1. Global Bile Duct Cancer Market Share (%) in Terms of Value, By Region, 2021

Rising research and development activities by pharmaceutical companies is expected to aid in the growth of the global bile duct cancer market

For instance, in 2015, Leap therapeutics, developed a humanized monoclonal antibody DKN-01 which is under clinical trial phase I for treatment of bile duct cancer through its anti-neoplastic activity.

Furthermore, in September 2019, Merck Sharp & Dohme Corp, a pharmaceutical company, initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment of cholangiocarcinoma (bile duct cancer). The study is currently in Phase 3 clinical trials and is expected to be completed by August 2023.

Bile Duct Cancer Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 185.4 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	12.8%	2028 Value Projection:	US$ 429.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Treatment Type: Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy (Pembrolizumab (Phase 3)), Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P. and Delcath Systems, Inc.
Growth Drivers:	Increasing prevalence of cholangiocarcinoma Increasing drug approvals and launches
Restraints & Challenges:	High cost of bile duct cancer treatment

Figure 2. Global Bile Duct Cancer Market Share (%), by Distribution Channel, 2021

Global Bile Duct Cancer Market– Impact of Coronavirus (COVID-19) Pandemic- Government Initiatives to Combat COVID-19

COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets

Furthermore, in May 2020, the Government of India announced relief for an amount of US$ 13.3 per person for daily wagers and construction workers for all states and union territories

In June 2020, All of Us Research Program, part of the National Institutes of Health, announced COVID-19 research initiatives through antibody testing. The study collaborators include the Frederick National Laboratory for Cancer Research, supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases along with the Centers for Disease Control and Prevention.

Hence, increasing research and development of drugs is expected to drive the cholangiocarcinoma market growth.

Global Bile Duct Cancer Market Restraint

Expensive treatments of bile duct cancer on a global level is expected to hamper the market growth over the forecast period.

According to the data published in UCL School of Pharmacy report 2020, oncology treatment (including chemotherapy, targeted therapy, and others) related costs in the U.K. are approximately 0.1 to 0.15% of GDP or accounts 20 to 25% for oncology treatments.

High cost associated with the treatment of cholangiocarcinoma patients is expected to hamper the market growth. According to the U.S. National Library of Medicine report 2017, the total cost of treatment for cholangiocarcinoma in year 1997 was US$ 36,460 and US$ 77,753 in 2012.

Key Players

Major players operating in the global bile duct cancer market include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.

Table of Content

*Browse 26 market data tables and 27 figures on "Bile Duct Cancer market” - Global forecast to 2028

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global bile duct cancer market during the forecast period (2021-2028)?

The global bile duct cancer market size is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% between 2021 and 2028.

What are the major factors driving the market growth?

Increasing prevalence of cholangiocarcinoma, drug approvals and launches are expected to drive the market growth over the forecast period.

Which is the leading treatment type segment in the market?

Chemotherapy segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering growth of the market?

Major factors hampering growth of the bile duct cancer market include the high cost of bile duct cancer treatment.

Which are the major players operating in the market?

Major players operating in the market include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.